Study Title
Statin Use and the Risk of Incident Dementia
American Medical Association

Thomas D. Rea, MD, MPH; John C. Breitner, MD; Bruce M. Psaty, MD, PhD; Annette L. Fitzpatrick, PhD; Oscar L. Lopez, MD; Anne B. Newman, MD, MPH; William R. Hazzard, MD; Peter P. Zandi, PhD, MPH; Gregory L. Burke, MD, MS; Constantine G. Lyketsos, MD, MHS;


Background: Statins (3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitors) reduce cardiovascular risk through mechanisms that might affect the development of dementia.
Objective: To evaluate whether statin use is associated with a lower risk of dementia compared with never use of lipid-lowering agents (LLAs).
Design: Cohort study of community-dwelling adults 65 years and older. The analysis included 2798 partici- pants free of dementia at baseline.
Main Outcome Measures: Using Cox proportional hazards regression analysis, we estimated the risk of in- cident all-cause and type-specific dementia associated with time-dependent statin therapy compared with never use of LLAs. The primary analyses incorporated a 1-year lag between exposure and outcome. Secondary analyses in- cluded the final year of exposure and modeled statin use as current use vs nonuse to simulate a case-control approach.
Results: Compared with never use of LLAs, ever use of statins was not associated with the risk of all-cause de- mentia (multivariable-adjusted hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.77-1.52), Alzheimer dis- ease alone (HR, 1.21; 95% CI, 0.76-1.91), mixed Alzhei- mer disease and vascular dementia (HR, 0.87; 95% CI, 0.44-1.72), or vascular dementia alone (HR, 1.36; 95% CI, 0.61-3.06). In contrast, in secondary analyses, cur- rent use of statins compared with nonuse of LLAs was associated with HRs of 0.69 (95% CI, 0.46-1.02) for all- cause dementia and 0.56 (95% CI, 0.35-0.92) for any Alz- heimer disease.
Conclusions: In this cohort study, statin therapy was not associated with a decreased risk of dementia. Methodological differences may explain why results of this cohort investigation differ from those of prior case-control studies. Additional investigation is needed to determine whether and for whom statin use may affect dementia risk.

March 1, 2005
View study

Share This

Related Topics


Dr. Perlmutter is one of the leading lights in medicine today, illuminating the path for solving chronic illness

Mark Hyman, MD